RFA-TR-22-032: Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (U43/U44 - Clinical Trail Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to small businesses. Applications closed on August 21, 2023.
From the official notice on Grants.gov, last changed September 19, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
Projects funded under RFA-TR-22-032 were run by National Center for Advancing Translational Sciences (NCATS, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-TR-22-032 in the NIH Guide.
Key dates
| Posted | September 19, 2022 |
|---|---|
| Deadline | August 21, 2023 |
| Archived by Grants.gov | September 26, 2023 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components- are not allowed.
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (78% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This FOA provides support using the SBIR cooperative agreement mechanisms for the development, regulatory qualification and commercialization of alternative approaches methods (NAMs) that specifically utilizes the neuromuscular junction Tissue Chips (TC) platforms that will replace the LD50 assay (mouse lethality bioassay (MLB) as a potency assay for botulinum toxin. The NIH NCATS and FDA are partners in this FOA and will collaborate and coordinate efforts with award recipients. The goal of this collaboration is to establish the Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) as a Drug Development Tool (DDT). A main objective for this funding opportunity would be to position BoT PATCh as an alternative test method that can be utilized as a stand-alone replacement for MLB. As a cooperative agreement, small business concerns (SBCs) will be expected to work with NIH and FDA staff to develop and implement the final validation plan for the proposed alternative test method.
Funded under RFA-TR-22-032 so far
NIH funded 2 projects under RFA-TR-22-032 in fiscal 2023 to 2025, at 2 institutions. The median yearly award was $910,019.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| High-Throughput NMJ Assay for Botox Potency Screening | Curi Bio Inc | 2025 | $901,175 |
| Human NeuromuscularJunction Platform to Evaluate Botulinum Toxin Potency | Hesperos, Inc | 2025 | $1.0 million |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Who has won National Center for Advancing Translational Sciences grants before
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 15 | $95.3 million |
| Vanderbilt University Medical Center | Tennessee | 10 | $94.6 million |
| Duke University | North Carolina | 11 | $88.9 million |
| University of North Carolina at Chapel Hill | North Carolina | 16 | $74.5 million |
| The Johns Hopkins University | Maryland | 20 | $70.7 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-TR-22-032 still open?
No. It closed on August 21, 2023.
Who can apply for Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (U43/U44 - Clinical Trail Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (U43/U44 - Clinical Trail Not Allowed)?
Closed August 21, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-TR-22-032?
NIH RePORTER lists 2 projects funded under RFA-TR-22-032 in fiscal 2023 to 2025, at 2 institutions. The most were at Curi Bio Inc, Hesperos, Inc.
Who has won National Center for Advancing Translational Sciences grants before?
The largest recipients over five fiscal years were University of Pittsburgh - of the Commonwealth System of Higher Education, Vanderbilt University Medical Center, Duke University. The program made 867 awards worth $3.1 billion in that time.
Similar open grants
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)